Anti schizophrenic antibody or a fragment of KNN, understand its composition and treatment of inflammation

摘要

1. Claim 1: an anti schizophrenic antibody or a fragment combined with Kuwait Petroleum Company, characterized in that the antibody or fragment contains (a) a cdr-h1 containing the amino acid sequence SEQ ID 28; (b) a cdr-h2 containing the amino acid sequence SEQ ID 29; (c) a CDR-H3 containing the amino acid sequence SEQ ID 29, including: 29. Amino acid sequence of SEQ ID 30; (d) cdr-l1, including amino acid sequence of SEQ ID 31; (E) cdr-l2, including amino acid sequence of SEQ ID 32;(f) a cdr-l3, comprising SEQ ID amino acid sequence No. 33. 113. Claim 14: a pharmaceutical ingredient characterized by the presence of antibodies in any 1-13 claims or antibody fragments combined with CDU. Requirement 17: typical nucleic acidsBecause it will antibody or link to the RCD part from any 1-13 requirement. 19. Claim 20: a vector 17-19 having the property of containing the nucleic acid in any claim. Claim 23: claim unit 22The characteristic is that the host cell is composed of a first vector and a second vector, Among them, the first carrier includes a nucleic acid that can encode a heavy chain, while the second carrier includes a nucleic acid that can encode a lighter antibody chain, or a fragment in any 1-13 claims that combines with the antibody of CDU. Claim 32: a method for the treatment of inflammation, characterized by the effective supply of antibodies to patients in need of such treatment or part of 1-13 antibodies combined with CDU,This is about inflammation.